Influenza Medications Market - Drug Type (Antiviral [Single, Combination], Antihistamines), Influenza Type (A, B), Age Group, Route of Administration (Oral, Inhaled), Type (Branded, Generic), Medication, Distribution Channel, Global Forecast (2024 – 2032)

Influenza Medications Market Size

Influenza Medications Market size in 2023 was valued at USD 942.6 million and is anticipated to showcase growth at 2.9% to reach USD 1.2 billion by 2032. One of the major factors contributing to the growth of this market is the increasing prevalence of influenza.
 

For instance, Centers of Disease Control and Prevention (CDC) estimated that during the 2022-2023 season, influenza was associated with 31 million illnesses, 14 million medical visits, 360,000 hospitalizations, and 21,000 deaths in the U.S. Such high number of cases of influenza, necessitate the need for effective treatments, thereby aiding in market growth. In addition, pharmaceutical companies are investing in the development of novel antiviral agents with unique mechanisms of action against influenza viruses. Furthermore, the advanced influenza diagnostic tests including the development of rapid influenza diagnostic tests facilitates early diagnosis of disease and treatment, further fostering the market growth.
 

Influenza medication refers to pharmaceutical drugs and treatments specifically designed to prevent, manage, or alleviate the symptoms of influenza, commonly known as the flu. These medications include antiviral drugs, antihistamines, and others. These medications are prescribed or recommended by healthcare professionals and are available in various forms, including oral medications, inhalation medications, and injectable medications.
 

Influenza Medications Market Trends

• With the rising number of influenza cases there is a greater demand for medications to treat and prevent the illness, driving growth in the market.
   
• There has been growing awareness among both healthcare professionals and the public about the importance of early detection and treatment of influenza. Additionally, the availability of effective treatments, such as antiviral drugs, has led to greater adoption of influenza medications among healthcare professionals and patients. As a result, more individuals are seeking treatment for influenza symptoms, leading to increased growth of market.
   
• Furthermore, pharmaceutical companies and research institutions are actively engaged in research and development activities aimed at discovering and developing new influenza drugs. These efforts are driven by the need to address challenges such as antiviral resistance, limited treatment options, and the potential for future influenza pandemics, further fostering the market expansion.
   

Influenza Medications Market Analysis

The global market based on drug type is segmented into antiviral drugs, antihistamines, analgesics, and antipyretics. The antiviral drugs segment is sub-segmented into single antiviral drugs and combination antiviral drugs. The antiviral drugs segment dominated the global market with 55.2% of business share in 2023.
 

• Antiviral drugs are considered the primary treatment for influenza infections. These are crucial in the management and treatment of influenza, as they directly target the virus to reduce its severity and duration. The effectiveness of antiviral drugs in treating influenza has led to their widespread use, especially during flu seasons.
   
• Additionally, antiviral drugs such as oseltamivir (Tamiflu) and zanamivir (Relenza), are widely available and accessible in many regions worldwide.
   
• Moreover, the development of new antiviral drugs with improved efficacy and safety profiles has further boosted the market share of this segment.

The global influenza medications market based on influenza type is categorized into influenza A and influenza B. The influenza A segment was valued at USD 704.1 million in 2023.
 

• Influenza A viruses are responsible for most seasonal influenza outbreaks and can cause more severe illness compared to Influenza B viruses. These strains are known to circulate widely and cause significant morbidity and mortality, leading to a higher demand for medications to treat and prevent Influenza A infections.
   
• The widespread availability and prescription of antiviral drugs and increased use of influenza vaccines to prevent influenza A, contribute to the dominance of Influenza A segment in the market.
   

The influenza medications market based on age group is classified into adults, pediatrics, and geriatric. The adults segment accounted for significant market share and is expected to witness growth at 3% from 2024 – 2032.
 

• Adults typically experience higher rates of influenza incidence compared to pediatric and geriatric populations. They are often more exposed to influenza viruses in workplaces, public spaces, and social settings, leading to increased susceptibility to infection.
   
• Additionally, adults often experience more severe symptoms compared to children, requiring more intensive medication and care.
   
• Thus, the higher incidence rates along with increased severity of the disease drives higher demand for influenza medications among adults.
   

The influenza medications market based on route of administration is divided into oral, inhaled, and intravenous. The oral segment is expected to reach USD 1 billion by 2032.
 

• Oral medications are convenient and easy to administer, making them preferred by patients.
   
• The oral route of administration also allows for easier dose adjustments and titration, making it suitable for a wide range of patient populations, including children and the elderly.
   
• Moreover, oral medications are often more cost-effective compared to other administration routes, such as intravenous or inhalation therapies, due to lower manufacturing and administration costs. This cost-effectiveness makes oral medications an attractive option for both patients and healthcare systems, driving their market share in the market.

The influenza medications market based on type is segmented into branded and generic. The branded segment was valued at USD 755 million in 2023 and is predicted to experience growth at 2.5%.
 

• Branded medications are typically associated with established pharmaceutical companies that have a reputation for quality, efficacy, and safety. These medications are often result from extensive R&D efforts, including preclinical studies, clinical trials, and regulatory approvals, which contribute to their higher market share.
   
• Additionally, healthcare professionals are more likely to prescribe branded medications, further contributing to the higher market share of this segment.
   

The influenza medications market based on medication is categorized into prescription and OTC. Prescription medication segment held notable market share of 75.2% in 2023.
 

• Prescription medications are often more potent and specific in targeting the influenza virus compared to over-the-counter options, leading to higher efficacy rates.
   
• Additionally, the potential for severe complications from influenza, especially in high-risk populations such as the elderly, young children, and individuals with underlying health conditions, drives the demand for prescription medications that can provide more effective treatment and reduce the risk of complication.
   
• The prescription segment's dominance is also supported by the healthcare system's role in prescribing and monitoring the use of these medications to ensure optimal outcomes for patients.
   

The influenza medications market based on distribution channel is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment dominated the market in 2023.
 

• Hospitals serve as the primary point for patient care with a higher volume of patients compared to other healthcare settings. Hence, hospital pharmacies cater to a greater demand for influenza medications.
   
• Moreover, hospital pharmacies are staffed by pharmacists with clinical expertise who work closely with healthcare providers to ensure accurate and safe medication management for patients.
   
• Furthermore, the strict regulation and control over the distribution and use of medications make hospital pharmacies the preferred and regulated source for these drugs, contributing to their dominance in the market.

North America dominated the global influenza medications market in 2023 and is predicted to grow at a CAGR of 2.7% over the analysis period to reach USD 548.7 million by 2032.
 

• The region experiences a significant burden of influenza infections annually, with millions of cases reported each year. Factors such as population density, international travel, and seasonal variations contribute to the widespread transmission of influenza viruses in the region, leading to a high demand for influenza medications.
   
• Additionally, well-developed healthcare infrastructure with advanced medical facilities, including hospitals, clinics, and pharmacies further enhances the regional market growth.
   

Influenza Medications Market Share

The influenza medications industry is characterized by the presence of several key players competing to meet the demand for effective treatments and preventive measures against influenza. The competitive landscape of the influenza medications market is dynamic and driven by factors such as technological advancements, regulatory developments, public health initiatives, and changing consumer preferences. Market players are constantly involved in innovation, collaboration, and new product launches to maintain a competitive edge in the market.
 

Influenza Medications Market Companies

Leading players operating in the influenza medications industry include:

• AstraZeneca plc
• BioCryst Pharmaceuticals, Inc.
• Daiichi Sankyo Company
• F. Hoffmann-La Roche AG
• GlaxoSmithKline plc
• Lupin
• NATCO Pharma Limited
• Novartis AG
• Sanofi
• Teva Pharmaceutical Industries Ltd.
   

Influenza Medications Industry News

• In August 2022, Genetech announced the U.S. FDA approval of Xofluza, an antiviral drug to treat influenza children aged 5 and older. The approval helped the company to strengthen its product portfolio and increase their revenue.
   
• In August 2022, Roche announced the approval of a supplemental New Drug Application (sNDA) for Xofluza, allowing its use in treating acute uncomplicated influenza among otherwise healthy children aged five to less than 12 years who have exhibited symptoms for no longer than 48 hours. This approval provided the company with significant opportunities for market expansion and enhance their product portfolio.
   

The influenza medications market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2018 to 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Drug Type

• Antiviral drugs
  • Single antiviral drugs
  • Combination antiviral drugs
• Antihistamines
• Analgesics
• Antipyretics

Market, By Influenza Type

• Influenza A
• Influenza B

Market, By Age Group

• Adults
• Pediatric
• Geriatric

Market, By Route of Administration

• Oral
• Inhaled
• Intravenous

Market, By Type

• Branded
• Generic

Market, By Medication

• Prescription
• OTC

Market, By Distribution Channel

• Hospital pharmacies
• Retail pharmacies
• Online pharmacies

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • Rest of Middle East and Africa